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Abstract
Background:  The aim of the present study was to determine the prognostic relevance of
thymidine labeling index (TLI) in patients with breast cancer.
Methods: TLI of the primary tumor was measured in 268 patients at the time of the surgical biopsy
by an in vitro method.
Results: Fifty-four patients had stage I disease, and 138 patients had stage II disease, and 76 patients
had stage III disease. One hundred-four patients were found to have low TLI-index (<3%), and 164
patients had high TLI-index (≥3%). The median follow-up was 71.5 months (range, 6–138 months).
The 5-year overall survival (OS) and disease free survival (DFS) rates was 84% and 74%,
respectively. Lymph node involvement, tumor size more than 2 cm, high nuclear grade and estrogen
receptor negativity were found to be associated with poorer DFS and OS rates. On subgroup
analysis, however, the 5-year OS rate was significantly higher in the low TLI-group than in the high
TLI-group in patients with stage I disease (100% vs 76%, p = 0.05).
Conclusion: Our findings suggest that the prognostic significance of TLI appears to be limited to
early breast cancer that might help to distinguish patients who need more aggressive adjuvant
treatment.
Background
The determination of prognosis of a patient with breast
cancer is extremely important due to the complex biology
of cancer. Great efforts have been made to separate
patients who need agressive systemic treatment due to
high-risk of recurrence, from those in whom loco-regional
treatment is sufficient. For this purpose, increasing
number of biological markers such as hormone receptors,
bcl-2, p53 mutations, c-erbB2 over-expression, Ki-67,
nuclear DNA ploidy, and microvessel density have been
proposed as potential prognostic markers in breast cancer
[1-5]. Many of these markers appeared to be promising in
initial reports but eventually failed to maintain their pre-
dictive value on clinical outcome. Among these markers,
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the proliferative rate of tumor cells, as estimated by differ-
ent approaches, has drawn great attention as a prognostic
factor. Proliferative activity of the tumor cells utilizing H3-
thymidine labeling index (TLI) has been a reliable and
reproducible method. As a dynamic measurement of de
novo DNA synthesis, TLI reflects the percentage of cells in
the S-phase fraction of the cell cycle [6]. Although there
are several studies that emphasize proliferative index of
tumor could provide relevant information on prognosis
of patient with breast cancer and on prediction of
response to treatment, debate still remains [7-11]. The
main reasons for the conflicting results might be due to
the techniqual difficulties in quantifying TLI and the het-
erogenicity of patient series.
In this study, we investigated the prognostic value of TLI
in our patient population with operable breast cancer by
analyzing various associations between TLI and tumor
characteristics and outcome by comparing with other pre-
viously established prognostic factors.
Patients and methods
Between April 1993 and February 2000, 268 consecutive
patients with operable breast cancer treated at the Breast
Cancer Research and Treatment Unit at the Istanbul Uni-
versity, Istanbul Medical School, were retrospectively ana-
lyzed. The study was approved by the university ethics
committee, and all participating patients gave informed
consent. Patients with systemic metastases at the time of
diagnosis (n = 33), and patients with neoadjuant chemo-
therapy (n = 35) were excluded from the study. Medical
records were reviewed to collect the following data: age,
menopausal status, type of surgery performed (mastec-
tomy or breast conserving surgery), tumor characteristics
(tumor size, nuclear and histological grade, histological
type, presence of lymphovascular invasion, status of estro-
gen and progesterone receptors, presence of multifocality
or multicentricity), nodal status, stage, adjuvant treatment
(endocrine therapy, chemotherapy, radiotherapy), local
and systemic recurrences, follow-up time. Histological
and nuclear grades of the primary tumors were deter-
mined according to the Richardson-Bloom grading sys-
tem [12]. The 6th edition of the AJCC Cancer Staging
system was used for staging [13].
Assessment of Thymidine Labeling Index
Thymidine labeling index was determined immediately
after surgical biopsy of tumor samples obtained from
patients with breast cancer as described before [9]. Briefly,
the tumor was minced into 8–10 fragments of about 1
mm3. The minced fragments were placed in 2 mL of 199
medium (Biological Industries, Kibbutz Beit Haemek,
Israel) containing 20% fetal calf serum (Biological Indus-
tries, Kibbutz Beit Haemek, Israel), streptomycin 100
microg/ml, penicillin 100 U/mL, and 6 micro Ci/mL H3-
thymidine with specific activity 5 Ci/mol (Radiochemical
Center, Amersham Life Science, UK). They were incubated
for 1 hour at 37°C in shaker water bath. After the incuba-
tion period, the tumor fragments were washed 3 times in
phosphate-buffered solution, and fixed in buffered 10%
formalin solution dehydrated in alcohol, and embedded
in parafin. Paraffin sections were obtained cut at 5
micron. Slides were coated with emulsion film (Ilford K2,
Mobberley Cheshire, UK) in a dark room and exposed at
4°C for 3–5 days. Autoradiographies were then developed
in D 19 b 5 minutes at 18°C, and fixed in a standart fixer.
The slides were stained with hematoxylin and eosin at
4°C. A total of 1000–3000 cells were counted to deter-
mine the ratio of labeled cells. A tumor cell was consid-
ered labeled with thymidine when it contained at least 20
grains overlying the nucleus. Thymidine labeling index
was estimated as the percentage of epithelial cells labeled
with thymidine. Values less than 3% were considered as
low TLI, whereas values equal to or more than 3% were
considered high TLI based on previous studies [14-18].
Follow-up
Patients were followed up with history and physical exam-
ination at least every 3 months for the first 2 years and
then every 6 months for the next 2 years and then annu-
ally thereafter, if they were free of disease. Mammography
of the breast along with chest X-ray, liver ultrasound, bone
scintigraphy and biochemical screening were obtained in
patients with high likelihood of recurrence once a year.
Loco-regional and distant relapses were diagnosed by
imaging techniques and/or biopsy.
Statistical Analysis
The SPSS 10.1 software package (SPSS Inc., Chicago, IL)
was used for statistical analyses. Patients were tabulated
according to their TLI status whether they had tumors
with low or high TLI. Associations between TLI and vari-
ous factors such as patient and tumor characteristics and
outcome were investigated. Chi-square test was used in
univariate comparison analyses. Disease-free survival
(DFS) time was considered as the interval between the
date of first diagnosis of the tumor and the date of the first
documented evidence of new disease manifestation in
locoregional or distant sites. Overall survival (OS) time
was defined as the interval between the first diagnosis of
the tumor and the date of the last follow-up or death.
Patients who were alive or had died of any cause were cen-
sored for analysis of OS. Kaplan-Meier survival test was
used in survival analyses. Survival rates were compared by
log-rank test. Variables that were found to be significant in
univariate Kaplan-Meier survival analyses or thought to be
clinically significant such as TLI were further evaluated in
multivariate Cox regression model to determine the inde-
pendent factors associated with OS or DFS rates. A p-valueWorld Journal of Surgical Oncology 2007, 5:93 http://www.wjso.com/content/5/1/93
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of less than or equal to 0.05 was considered to be statisti-
cally significant.
Results
Patient and tumor characteristics
Patient and tumor characteristics were shown in Table 1
and 2. The median age of patients was 50 years (range 23–
87 years), and 161 patients (60.5%) were postmenopau-
sal. One hundred eighty-two patients (67.9%) underwent
modified radical mastectomy, and 86 patients (32.1%)
had breast conserving surgery with complete axillary dis-
section. According to the AJCC staging criteria, 54 patients
(20.1%) had stage I disease, 138 patients had stage II dis-
ease (51.5%), and 76 patients (28.4%) had stage III dis-
ease. Two-hundred five patients (76.5%) received
adjuvant chemotherapy, and 187 patients with estrogen
and/or progesterone receptor positivity (69.8%) received
hormonal therapy. All patients with breast conservation
and 114 patients with mastectomy had also radiation
therapy followed by surgery.
One hundred-four patients (38.8%) were found to have
low TLI, and 164 patients (61.2%) had high TLI. When
associations between TLI and other patient or tumor char-
acteristics were investigated, patients with high TLI were
less likely to receive hormonal therapy than patients with
low TLI (low TLI-group, 56.7%, vs. high TLI-group,
43.3%, p < 0.021). Furthermore, patients with high
nuclear grade were also more likely to have high TLI val-
ues compared with patients with low or intermediate
nuclear grade (low & intermediate NG, 55.4%, vs. high
NG, 72.5%, p = 0.008). However, no other significant
associations could be found between TLI and other
parameters (Table 1 and 2).
Outcome
The median follow-up was 71.5 months (range, 6–138
months). The 5-year overall survival (OS) and disease free
survival (DFS) rates were 84% and 74%, respectively. Dur-
ing the follow-up period, loco-regional recurrence was
observed in 8 of 104 (7.7%) patients with low TLI and in
7 of 164 patients (4.3%) with high TLI. Moreover, distant
metastases were found in 26 patients (25.0%) among
patients with low TLI, and in 26 patients (28.7%) among
patients with high TLI, respectively.
As would be expected from previous numerous studies,
lymph node involvement, tumor size more than 2 cm,
high nuclear grade and estrogen receptor negativity were
found poor prognostic factors associated with decreased
DFS and OS rates compared with others (Table 3). Pres-
ence of lymphovascular invasion (LVI) in breast tumors
was associated with decreased 5-year-DFS and OS rates in
patients compared with others, but these associations did
not reach the statistical significance (LVI+, 69.2% vs LVI-,
74.7%, p = 0.088 for 5-year DFS, and LVI+, 63.5% vs LVI-
, 70.6%, p = 0.058 for 5-year OS). Furthermore, no signif-
icant difference could be found in 5-year disease free sur-
vival rates between all patients with low TLI and high TLI
(76.9% for low TLI vs 72.4% for high TLI, p = 0.353, Fig-
ure 1a). On the other hand, patients with low TLI were
found to have higher 5-year OS rates than patients with
high TLI but it did not reach statistical significance (75.4%
for low TLI vs 64.8% for high TLI, p = 0.084, Figure 1b).
On subgroup analyses among patients with stage I disease
however, patients with low TLI were significantly found to
have improved 5-year OS-rates compared with patients
with high TLI (low TLI, 100% vs high TLI, 76%, p = 0.05,
Figure 2). Among patients with stage II similarly, patients
with low TLI were found to have better 5-year OS rates
compared with patients with high TLI, but this association
did not reach the statistical significance (95.4% for low
TLI vs 89.7% for high TLI, p = 0.07, Figure 3). No other
significant associations could be found between TLI and
5-year OS or DFS rates in other subgroups as shown in
Table 4.
When variables that were found to be significant in uni-
variate Kaplan-Meier survival analyses or thought to be
clinically significant were further evaluated in multivari-
ate Cox regression model, node positivity (HR [vs. other]
= 2.6; 95% CI, 1.5–4.5; P = 0.001), and tumor size > 2 cm
(HR [vs. other] = 2.1; 95% CI, 1.2–3.7; P = 0.010) were
independent predictors of decreased 5-year DFS (Table 5).
Similarly, node positivity (HR [vs. other] = 2.3; 95% CI,
1.2–4.4; P = 0.012), and estrogen receptor negativity (HR
[vs. other] = 1.9; 95% CI, 1.0–3.4; P = 0.036) were also
found as independent predictors of decreased 5-year OS
(Table 6). However, the other factors including TLI failed
to show a significant independent predictive value for
DFS or OS on multivariate analyses in this study group
(Table 5 and 6).
Discussion
Several prognostic factors such as tumor size, lymph node
involvement, nuclear and histologic grade, and hormone
receptor status are commonly used together in predicting
the clinical outcome of patients with breast cancer rather
than a single parameter. Investigations are going on to
find out an ideal prognostic factor which separates the
patients into low risk and high risk groups in terms of the
probability of recurrence. In the meta-analysis by Mirza et
al. [19], studies with sample size more than 200 and fol-
low-up more than 5 years were evaluated and tumor size,
tumor grade, cathepsin-D, Ki-67, S-phase fraction, mitotic
index, and vascular invasion were found to be associated
with survival outcome in patients with early-stage node-
negative breast cancer. Because of the techniqual difficul-
ties and variations in the measurement of many of these
factors, tumor size and tumor grade have been accepted asWorld Journal of Surgical Oncology 2007, 5:93 http://www.wjso.com/content/5/1/93
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Table 1: Associations of patient characteristics with the TLI status.
All patients Patients with TLI-low Patients with TLI-high p-value
n% n %n%
Age 0.900
≤50 years 136 50.7 52 38.2 84 61.8
>50 years 132 49.3 52 39.4 80 60.6
Menopausal status 0.559
Premenopausal 105 39.5 38 36.2 67 63.8
Postmenopausal 161 60.5 64 39.8 97 60.2
Tumor 0.306
pT1 103 38.4 44 42.7 59 57.3
pT2+pT3+pT4 165 61.6 60 36.4 105 63.6
Node 0.448
pN0 114 42.5 41 36.0 73 64.0
pN(+) 154 57.5 63 40.9 91 59.1
Stage 0.596
I 5 42 0 . 1 1 8 3 3 . 33 66 6 . 7
II 138 51.5 54 39.1 84 60.9
III 76 28.4 32 42.1 44 57.9
Type of surgery 0.330
Breast conservation 86 32.1 37 43.0 49 57.0
Mastectomy 182 67.9 67 36.8 115 63.2
Radiation therapy 0.911
Yes 200 74.6 78 39.0 122 61.0
No 68 25.4 26 38.2 42 61.8
Hormonal Therapy 0.021
Yes 187 69.8 81 43.3 106 56.7
No 81 30.2 23 28.4 58 71.6
Chemotherapy 0.451
Yes 205 76.5 77 37.6 128 62.4
No 63 23.5 27 42.9 36 57.1
Table 2: Associations of tumor characteristics with the TLI status.
All patients Patients with TLI-low Patients with TLI-high p-value
n% n %n%
Histologic type 0.556
Invasive ductal 182 67.9 72 39.6 110 60.4
Invasive lobular 18 6.7 9 50.0 9 50.0
Mixed ductal&lobular 50 18.7 18 36.0 32 64.0
Other 18 6.7 5 27.8 13 72.2
Multifocality + Multicentricity 0.456
Yes 34 12.7 11 32.4 23 67.6
No 234 87.3 93 39.7 141 60.3
Nuclear Grade 0.008
1+2 177 66 79 44.6 98 55.4
3 91 34 25 27.5 66 72.5
Histologic Grade 0.999
1+2 136 50.7 53 39.0 83 61.0
3 132 49.3 51 38.6 81 61.4
Lymphovascular invasion 0.753
Yes 206 76.9 81 39.3 125 60.7
No 62 23.1 23 37.1 39 62.9
Estrogen receptor (ER) status 0.124
ER-positive 173 64.6 73 42.2 100 57.8
ER-negative 95 35.4 31 32.6 64 67.4
Progesteron receptor (PR) status 0.134
PR-positive 69 25.7 32 46.4 37 53.6
PR-negative 199 74.3 72 36.2 127 63.8World Journal of Surgical Oncology 2007, 5:93 http://www.wjso.com/content/5/1/93
Page 5 of 9
(page number not for citation purposes)
the only markers that currently had widespread clinical
usefulness in these patient group [19].
The prognostic and predictive relevance of tumor cell pro-
liferation expressed as TLI has been reported in many
studies [7-10]. Highly proliferative tumors are generally
related to shorter disease free and overall survival rates.
Significant correlation between the TLI value and the
aggressiveness of breast carcinoma was observed in the
majority of the studies, and TLI was found to be the most
significant prognostic indicator in regards to the survival
[4,10,20]. According to the Meyer's study [20] including
227 operable breast cancer who were treated by radical
mastectomy, the low TLI-group had a probability of
relapse risk of 20% at 4 years, in contrast to 52% for the
high TLI-group. Similarly, Tubiana et al. [7] reported the
recurrence rates of breast carcinoma as 25% and 62% in
patients with low and high TLI groups, respectively at a
10-year follow-up.
We previously reported that TLI was a strong independent
prognostic factor affecting OS in locally advanced breast
cancer among the other established clinical and biological
parameters [9]. In this study, we investigated the prognos-
tic relevance of TLI in 268 operable breast cancer. We
could not demonstrate any significance of TLI to predict
survival in univariate and multivariate analyses in this
study group in concordance with our previous study
Table 4: Associations between TLI status and OS or DFS rates of 
the patient subgroups
5-year 
DFS 
rate 
(%)
P-value 5-year 
OS 
rate 
(%)
P-value
Patients with adjuvant 
chemotherapy (n = 205)
0.272 0.224
Low TLI 75 89
High TLI 68 80
Patients without adjuvant 
chemotherapy (n = 63)
0.663 0.634
Low TLI 83 95
High TLI 89 96
Patients with adjuvant 
hormonal therapy(n = 187)
0.512 0.824
Low TLI 79 89
High TLI 78 89
Patients without adjuvant 
hormonal therapy (n = 81)
0.933 0.164
Low TLI 69.4 88.9
High TLI 63.5 74.4
Patients with stage I (n = 
54)
0.474 0.05
Low TLI 88.2 100
High TLI 78.7 76.4
Patients with stage II (n = 
138)
0.464 0.070
Low TLI 79.8 95.4
High TLI 74.2 89.7
Patients with stage III (n = 
76)
0.526 0.800
Low TLI 65.7 76.3
High TLI 63.2 73.4
Patients with node-negative 
disease (n = 114)
0.994 0.188
Low TLI 83.5 92.6
High TLI 86.1 88.6
Patients with node-positive 
disease (n = 154)
0.142 0.113
Low TLI 72.6 86.4
High TLI 61.2 73.6
Table 3: Associations of patient and tumor characteristics with 
the disease free survival (DFS) and overall survival (OS) rates.
Variable 5-year 
DFS 
rate 
(%)
P-value 5-year 
OS 
rate
P-value
Age 0.745 0.319
≤50 years 74.3 76.1
>50 years 74.1 61.9
Tumor 0.002 0.001
pT1 83.4 81.9
Other (pT2+ pT3+pT4) 69.0 61.7
Node 0.0001 0.004
pN0 85.1 79.5
pN1+pN2+pN3 66.0 61.4
Nuclear Grade 0.007 0.032
1+2 76.4 70.5
36 7 . 7 6 6 . 7
Histologic Grade 0.080 0.093
1+2 78.9 75.9
36 7 . 2 6 1 . 2
Estrogen receptor 
status
0.030 0.016
ER-positive 78.1 74.3
ER-negative 64.6 59.1
Progesterone 
receptor status
0.331 0.567
PR-positive 79.0 71.1
PR-negative 71.4 68.2
Lymphovascular 
invasion
0.088 0.058
Yes 69.2 63.5
No 74.7 70.6
TLI status 0.353 0.084
Low TLI 76.9 75.4
High TLI 72.4 64.8World Journal of Surgical Oncology 2007, 5:93 http://www.wjso.com/content/5/1/93
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including 155 patients [21]. Furthermore, we were unable
to show any association between TLI and survival in 114
patients with lymph node negative disease in the current
study. However, on subgroup analyses according to the
stage, we interestingly found that low TLI may be a predic-
tor of improved overall survival in breast cancer with stage
I disease in concordance with previous studies [10]. This
disconcordance might be due to the different tumor sizes
along with other clinicopathologic features of patients
with lymph node negative disease compared to patients
with stage I disease in the current study. Among patients
with stage II disease moreover, better overall survival rates
were determined in patients with low TLI compared with
patients with high TLI, but this association did not reach
the statistical significance. Therefore, our results suggest
that TLI may be a useful prognostic marker in early-stage
breast carcinoma to determine further therapeutical inter-
ventions after surgery.
Besides its prognostic relavance, predictive value of TLI on
clinical response to different therapautic agents is also the
subject of debate [9,22-24]. Some retrospective studies
have shown no relation between TLI and response to neo-
adjuvant chemotherapy in patients with locally advanced
breast cancer [9]. A recent randomized prospective study
published by Amadori et al. [23] have reported that a DFS
advantage of adjuvant CMF exists in node negative
patients with high TLI values. On the current study,
patients were separately analysed in subgroups according
to the postoperative therapeutic approach in an attempt
to eliminate the discrepancy between groups, and no sig-
nificant associations could be found between TLI and sur-
vival on these subgroup analyses. Further studies are
required to determine the predictive value of TLI on clini-
cal response to treatment.
In the present study, high TLI value was detected more fre-
quently in breast cancer with high nuclear grade that
might be an indicator of a more aggressive tumor. Both
rapid proliferative capacity and increased nuclear grade
indicate the agressiveness of breast carcinoma, as reported
in many other studies previously [6,20,21]. However, we
could not find any other significant associations between
A) No significant difference could be found in 5-year disease free survival rates between all patients with low TLI and high TLI  (p = 0.353) Figure 1
A) No significant difference could be found in 5-year disease free survival rates between all patients with low TLI and high TLI 
(p = 0.353). B) Patients with low TLI had higher 5-year OS rates than patients with high TLI but it did not reach statistical sig-
nificance (p = 0.084).
Table 5: Multivariate cox regression analyses for factors affecting 
disease free survival rates.
Variable Hazard 
ratio
95% CI P value
Node positivity (positive vs negative) 2.6 1.5–4.5 0.001
Tumor size >2 cm (vs ≤2 cm) 2.1 1.2–3.7 0.010
Nuclear grade (high vs 
low&intermediate)
1.1 0.6–1.8 0.846
Histologic grade (high vs 
low&intermediate)
1.6 1.0–2.7 0.060
Lymphovascular invasion (positive vs 
negative)
1.3 0.8–2.2 0.309
Estrogen receptor (negative vs 
positive)
1.4 0.9–2.3 0.140
TLI (high vs low) 1.2 0.7–1.9 0.522World Journal of Surgical Oncology 2007, 5:93 http://www.wjso.com/content/5/1/93
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TLI and tumor or patient characteristics such as tumor size
or lymph node status. Some investigators have found pos-
itive association between TLI and tumor size as opposed
to our study [6]. Furthermore, consistent with our data,
other studies reporting analyses of large series have also
failed to show an association between the TLI and lymph
node status [17,20,25].
Potential causes for conflicting results in the studies on
TLI might be attributable to the difficulties in the method-
ological procedure to determine H3-TLI, to the lack of a
standard cut-off point of TLI to classify patients as low-TLI
and high-TLI group, and to the heterogenicity of patient
series including differing prognostic factors, treatment
modalities, and follow-up intervals. In this study, we
accepted the value of 3% for TLI as the cut-off point in
concordance with previous studies that found TLI as a sig-
nificant prognostic factor on the large series of primary
breast cancer by using this cut-off value [14-18]. Due to
the some difficulties in the methodology such as the
necessity to perform the assay on fresh samples and the
absence of availability in peripheral institutions, this pro-
cedure has not been used widely. Therefore, S-phase frac-
tion has been used more commonly to measure the
proliferative activity of breast tumors although there are
controversial reports of its prognostic value on survival of
breast cancer patients [19,26,27]. In order to facilitate the
assay of proliferative index, some techniqual modifica-
tions were performed in our clinic, and we currently use
the thymidine analog bromodeoxyuridine (BrdUrd)
instead of H3-TLI since 2000.
Our results suggest that the prognostic significance of TLI
appears to be limited in breast cancer except early breast
cancer to distinguish patients who need more aggressive
adjuvant treatment. However, other prognostic factors
rather than proliferative index should be generally consid-
ered in planning of the systemic treatment of the patients.
Investigations are still going on to find the ideal prognos-
tic factors in breast carcinoma that would assist clinicians
in decision-making process to select the appropriate ther-
apeutic interventions. For this purpose, microarray-based
gene expression profiling of human breast cancer recently
emerged as novel screening techniques to estimate
patient's risk of recurrence Using a multistep approach, a
21-gene assay (Oncotype DX) was recently developed for
use in paraffin-embedded tumor tissue to predict risk for
distant recurrence or death in lymph node-negative breast
cancer patients [28]. Approximately 250 genes, selected
from the published literature, genomic data-bases, path-
way analysis, and from microarray-based gene expression
profiling experiments, were considered as candidates. The
final gene list (16 cancer-related and five reference genes)
and summary score (Recurrence Score) algorithm for this
assay were developed by analyzing the results of three
independent preliminary breast cancer studies conducted
in a total of 447 patients [29]. All these microarray-based
gene expression analyses of breast cancer include also pro-
liferation related-gene analyses. By using this assay, a
recent study demonstrated that the Recurrence Score was
strongly associated with risk of breast cancer death among
ER-positive, and lymph node-negative patients not treated
with chemotherapy [30].
Among patients with stage II disease, patients with low TLI  were found to have improved 5-year overall survival rates  compared with patients with high TLI, but it did not reach  the statistical significance (p = 0.07) Figure 3
Among patients with stage II disease, patients with low TLI 
were found to have improved 5-year overall survival rates 
compared with patients with high TLI, but it did not reach 
the statistical significance (p = 0.07).
Among patients with stage I disease, patients with low TLI  were found to have improved 5-year overall survival rates  compared with patients with high TLI (p = 0.05) Figure 2
Among patients with stage I disease, patients with low TLI 
were found to have improved 5-year overall survival rates 
compared with patients with high TLI (p = 0.05).World Journal of Surgical Oncology 2007, 5:93 http://www.wjso.com/content/5/1/93
Page 8 of 9
(page number not for citation purposes)
Conclusion
Along with the novel microarray-based gene expression
analyses, TLI may be useful as a prognostic indicator of
the biological agressiveness of tumor in patients of early-
stage, especially those with stage I disease to select
patients who could benefit from systemic therapies
including chemotherapy. Further prospective, large-scale
studies are needed to reach a general consensus on the rel-
evance of H3-TLI as a prognostic or predictive indicator in
breast cancer.
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